1/4: My early read on the two @TheLancet adenovirus #COVID19 vaccine trials: AZ-Oxford, they seem to be getting virus neutralizing antibody in the 10 patients who received 2 doses, roughly similar to convalescent patients but too few patients in the PRNT arm, also T cells
2/4: Certainly worth pursuing in a phase 3, but similar to non-human primates may wind up being a partially protective vaccine, i.e., may reduce disease but not viral shedding or transmission? Critical to standardize VNA results across studies, presumably this will happen in OSW
3/4: Chinese Ad5 vaccine seems less encouraging, not everyone seroconverted, and more adverse reactions, but also may be worth pursuing in phase 3.
4/4: Critical to do a well-done phase 3 study of 10,000-30,000 volunteers to determine protection and safety. Nothing here that would prompt me to prematurely release these vaccines under emergency use authorization.
